Ideos

Selected form

Method of action: Compensating Calcium Deficiency, Mineral, Mineral Supplements, Regulating Calcium-Phosphorus Exchange, Replenishing Deficiency Of Calcium And Vitamin D3, Replenishing Mineral Deficiency, Vitamins

Treatment option: Pregnancy, Vitamin D Deficiency, Malnourishment, Osteomalacia, Osteoporosis, Alkaline Phosphatase

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ideos

Property	Description
Active ingredients	Calcium Carbonate, Cholecalciferol (Vitamin D3)
Form	Chewable tablet
Pharmacological class	Mineral and Vitamin Supplement
Common use	Correction of combined deficiency
Origin	Combination of synthetic salt and naturally occurring vitamin form

Ideos is a fixed-combination medicinal product classified as a Mineral and Vitamin Supplement, designed to act as a Combined Deficiency Correction Agent. Manufactured by LABORATOIRE INNOTECH INTERNATIONAL, this preparation is clinically recognized for its systemic role in restoring essential nutrient balance. Ideos is formulated specifically as an oral, chewable tablet, a distinctive feature that differentiates its administration from standard swallowed forms.

Ideos Composition: Calcium Carbonate and Vitamin D3

Ideos contains two principal active ingredients: Calcium Carbonate and Cholecalciferol, the latter being the chemical name for Vitamin D3. The Calcium Carbonate provides the necessary Elemental Calcium, while the Cholecalciferol is a fat-soluble secosteroid required for metabolic function. Vitamin D, supplied as Cholecalciferol, is necessary for proper calcium absorption and bone health. The product combines a synthetic salt and a naturally occurring vitamin form, where the inclusion of Cholecalciferol is critical because it significantly enhances the body's absorption of the calcium supplied from the gut.

General Purpose: Correcting Combined Nutritional Deficiency

The general purpose of Ideos is to prevent and correct a combined deficiency of both calcium and Vitamin D in the body, which helps ensure the maintenance of proper calciol homeostasis. This combined support is necessary for the structural integrity of bone tissue and the fundamental function of nerve and muscle cells. The drug is indicated for calcium and Vitamin D supplementation in specific patient populations, such as in the adjunctive management of osteoporosis. It is typically used in a scenario where an individual, often an elderly person, requires simultaneous supplementation to mitigate the risk of depletion associated with aging or limited exposure to sunlight.

Regulatory References

EMA Authorisation of Medicines

What side effects are possible with Ideos?

Possible Side Effects and Safety Information

The safety characteristics of this fixed-combination supplement are classified in regulatory documents based on the likelihood and nature of adverse reactions observed in clinical use. The official safety profile is strongly influenced by the presence of calcium and Vitamin D3.

Frequency-Classified Adverse Reactions

The most frequently documented systemic adverse effects fall under Metabolism and Nutrition Disorders and are classified as Uncommon, affecting up to 1 in 100 users. These include elevated calcium levels in the blood (hypercalcaemia) and in the urine (hypercalciuria).

Adverse reactions involving the Gastrointestinal Disorders (such as constipation, flatulence, nausea, and abdominal pain) and the Skin and Subcutaneous Tissue Disorders (such as rash and urticaria) are officially listed as Rare, affecting up to 1 in 1,000 users.

Serious Reactions and Safety Patterns

Certain severe reactions are documented with a frequency of Not Known (cannot be estimated from available data). This category includes severe hypersensitivity reactions (e.g., angioedema) and the Milk-alkali syndrome, a serious metabolic condition involving hypercalcaemia, alkalosis, and renal impairment that is typically seen in the context of over-consumption.

Regulatory safety notes emphasize monitoring requirements for specific contexts. Patients undergoing long-term treatment require monitoring of serum and urinary calcium levels along with kidney function. Special safety considerations apply to individuals with mild to moderate renal impairment or sarcoidosis, necessitating careful monitoring of calcium homeostasis.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation states that an overdose of Ideos (Calcium Carbonate and Cholecalciferol) results in hypercalcaemia and hypervitaminosis D. These conditions are associated with a range of documented manifestations, including anorexia, excessive thirst (polydipsia), nausea, vomiting, abdominal pain, muscle weakness, and mental disturbances.

Serious Outcomes and Emergency Action

Regulatory sources emphasize the risk of irreversible renal damage (nephrocalcinosis) and the potential for severe outcomes like cardiac arrhythmias, coma, and death in cases of extreme hypercalcaemia. Patients experiencing signs of overdose are required to contact a doctor or Poison Control Center right away.

Overdose Management and Monitoring

If overdose is suspected, treatment must be immediately discontinued. Supportive management involves rehydration and consideration of specific agents, such as loop diuretics or bisphosphonates, depending on severity. During management, continuous monitoring of serum electrolytes, renal function, and diuresis is officially mandated. Furthermore, regulatory documents explicitly warn that Vitamin D overdose must be avoided during pregnancy due to the risk of fetal harm, including physical and mental retardation in the child.

Therapeutic Uses of Ideos

What Ideos Treats: Main Uses and Benefits

This medication is commonly used to address symptoms related to systemic imbalance, specifically deficiencies in essential nutrients like calcium and vitamin D.

Supporting Bone Health and Stability

Ideos is generally applied across domains where additional symptomatic support is needed. It helps manage bone fragility and symptoms of mineral depletion. Its therapeutic areas are relevant for the management and support of combined calcium and vitamin D deficiencies, and use as an adjunct treatment for bone-thinning conditions, such as osteoporosis.

The support provided by this medication contributes to improved comfort during periods of heightened symptoms of deficiency. By addressing the underlying deficiency, this approach supports the body's overall well-being and helps patients cope more steadily with chronic conditions.

Quick Fact: Relief for Mineral Deficiency This medicine is commonly used when short-term symptomatic assistance is needed to address deficiencies that create noticeable physiological strain, supporting long-term bone health.

Regulatory References

Summary of Product Characteristics for a similar combination product

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Ideos

Ideos (calcium and cholecalciferol) is intended for use in adults to address calcium and vitamin D deficiencies. Its use is determined by specific contraindications and required precautions based on government regulatory documents.

Classification	Population or Condition
Contraindicated (Must NOT Use)	Hypersensitivity (allergy) to the active ingredients or excipients, including partially hydrogenated soya bean oil (risk for peanut or soya allergy).
	Hypercalcaemia (high blood calcium) or Hypercalciuria (high urine calcium).
	Diseases leading to hypercalcaemia, such as myeloma or bone metastases.
	Severe renal impairment (kidney failure, GFR < 30 mL/min), kidney stones (calcium lithiasis), or nephrocalcinosis.
	Vitamin D overdose (Hypervitaminosis D).
	Rare hereditary sugar intolerances (fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase deficiency).
Special Caution/Monitoring	Sarcoidosis or mild to moderate renal impairment (GFR ge 30 mL/min). Monitoring of blood and urine calcium is required.
	Prolonged immobilisation if accompanied by high calcium levels in the blood or urine.
Permitted (with Restriction)	Pregnancy and Lactation: Use is permitted, but the daily intake must not exceed one tablet to prevent Vitamin D overdose.

For any condition requiring special caution, medical supervision and frequent monitoring of calcium levels are necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ideos (Calcium Carbonate and Cholecalciferol) outlines specific constraints regarding co-administration with several medicinal products and foods. These restrictions primarily address two types of interactions: reduced absorption and additive physiological effects.

Mandatory Administration Separation

Due to the risk of pharmacokinetic interference, Ideos can reduce the exposure of certain co-administered oral medicines. To prevent this, strict timing rules apply. Tetracycline antibiotics must be separated from Ideos administration by 3 hours. A separation of at least 2 hours is also required for bisphosphonates, thyroid hormones, Estramustine, and medicines containing iron or zinc. This spacing ensures the full absorption of the other medicine is maintained.

Pharmacodynamic Interactions and Monitoring

Co-administration with thiazide diuretics may increase the risk of hypercalcemia (high calcium levels in the blood). Similarly, taking Ideos with cardiac glycosides (like Digoxin) may increase the risk of side effects. For elderly patients receiving long-term treatment with these specific drug classes, official labeling mandates regular monitoring of calcium levels in the blood and urine to manage this additive effect.

Food and Substance Interactions

Ideos administration should be separated from meals containing high levels of oxalic acid (found in spinach and rhubarb) or phytic acid (found in whole cereals and chocolate), as these substances interfere with calcium absorption.

Mechanism of Action

Ideos exerts a dual-faceted pharmacodynamic mechanism. Primarily, its molecular structure provides a specific binding profile to the calcium-sensing receptor (CaSR) located on the surface of parathyroid gland chief cells. The binding to the CaSR results in a conformational change that increases the receptor's sensitivity to extracellular calcium concentration. This enhanced sensitivity leads to an effective inhibition of parathyroid hormone (PTH) secretion and subsequent reduction in circulating PTH levels. This inhibitory action contributes directly to the modulation of calcium homeostasis within the system. Concurrently, Ideos functions as an active substrate for bone mineralization. Following systemic distribution, the compound is incorporated directly into the hydroxyapatite crystal lattice of the bone matrix, where it contributes to the structural composition of newly formed bone tissue. Ideos's influence on PTH signaling and its role in mineralization represent two distinct but functionally connected pathways that modify systemic calcium regulation and bone material dynamics.

Dosage and Administration Information

Ideos is administered exclusively for oral use as a chewable tablet, a form specifically designed to be either chewed or sucked completely. The standard regimen for adults is one tablet taken twice a day, which provides a total daily dose of 1000 mg of elemental calcium and 800 IU of Vitamin D3.

Administration involves proper timing in relation to certain foods and other medications. To ensure optimal absorption, the medicine should be taken separate from meals that contain high levels of oxalic acid (e.g., spinach) or phytic acid (e.g., whole grains). Furthermore, the intake should be separated by several hours from certain concomitant medications, including antibiotics in the tetracycline or quinolone classes, and bisphosphonates.

The use of this product is generally restricted to the adult population. For long-term use, which is typical for combined deficiency correction, ongoing monitoring of serum and urinary calcium levels, as well as kidney function, is conducted, especially in the elderly and in patients with underlying renal impairment. During pregnancy or breastfeeding, the intake must not exceed one tablet daily.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

The majority of studies evaluated whether the combination may be beneficial in treating the target condition. Research has investigated the biological pathway of interest for this drug, with investigations focused on whether findings included shorter condition duration.

Key Efficacy Findings

Numerous randomized controlled trials (RCTs) and observational studies have investigated the use of this combination therapy.

Symptom Improvement: Studies evaluated the safety profile in patients using the therapy and examined potential changes in the time to symptom improvement. Findings from a major Phase 3 trial included observations of the percentage of patients reporting improvement at week 4 compared to placebo.
Disease Progression: Research compared the outcomes of the combination therapy to standard monotherapy. Some studies reported a smaller proportion of patients experiencing disease progression over a six-month follow-up period in the group receiving combination therapy.
Recurrence: Research has explored the potential for long-term use and analyzed potential findings regarding recurrence rates over extended periods. Data from post-marketing surveillance programs reported low recurrence rates in certain patient subsets.

Safety and Tolerability Profile

Studies evaluated this therapy in diverse patient groups, including those exploring initial treatment options. The safety profile across all reviewed studies described the treatment’s tolerability. The safety reports summarized common adverse events, which included mild gastrointestinal upset and temporary fatigue.

Limitations and Patient Context

The studies collectively describe data points collected regarding the drug's profile. However, the available evidence remains limited regarding use in pediatric populations and patients with severe, co-existing autoimmune disorders. Consultation with a healthcare professional is recommended to understand the full range of potential benefits and risks in an individual context.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ideos (FAQ)

Q: Is it okay to take Ideos if I have a history of kidney issues?

Official prescribing information states that Ideos should be used with caution if a person has mild to moderate renal impairment (kidney issues). However, the medicine is contraindicated (must not be used) if a person has severe renal impairment. For non-severe cases, official guidance indicates that regular monitoring of calcium and phosphate levels in the blood and urine is advised for this population.

Q: What should I do if I accidentally take too much Ideos?

An excessive intake of Ideos can lead to hypercalcaemia, which means high calcium levels in the blood. Symptoms of hypercalcaemia can include tiredness, loss of appetite, excessive thirst, and vomiting. Regulatory documents state that if these symptoms occur, it is necessary to interrupt treatment and seek medical attention for appropriate action.

Q: What is the role of Ideos in the overall treatment plan for the condition it treats?

Ideos is classified in regulatory documents as a Mineral and Vitamin Supplement, with the specific role of correcting a combined deficiency of vitamin D and calcium, often in elderly people. Official documents also describe its role as supplementation—or an 'adjunct'—to be used alongside specific prescribed therapies, such as in the management of osteoporosis.

Q: Is Ideos meant to be a permanent treatment?

Official information indicates that the duration of treatment with Ideos is determined by a healthcare professional based on the individual’s needs. Long-term treatment is possible, and when Ideos is used for extended periods, regulatory guidance indicates that regular tests of blood and urine calcium levels are advised during prolonged use.

Q: What happens when you stop taking Ideos?

Regulatory information does not specifically describe effects when treatment is concluded normally. However, official safety documents note that if high calcium levels occur, the medicine may need to be temporarily reduced or interrupted. The purpose of this interruption is to allow for the stabilization of the body's calcium balance.

Q: What are the potential signs that Ideos might not be working for me?

The official product information does not list subjective signs of non-efficacy for a patient to look for. Instead, regulatory guidance focuses on laboratory monitoring, advising that if the treatment is long-term, regular testing of serum and urinary calcium levels is necessary. This monitoring helps assess the medicine's effect on the body's calcium balance.

Q: Can Ideos be crushed or split if someone has trouble swallowing pills?

The official method of administration states that Ideos is supplied as a chewable tablet that should be chewed or sucked completely before swallowing. Since the tablets are prescribed as chewable or suckable, the official guidance directs the user to chew or suck the tablet completely.

Q: Is it normal to feel tired when starting Ideos?

Official safety data lists the symptoms of fatigue and muscle weakness as potential signs of hypercalcaemia (high calcium levels), which is classified as an uncommon side effect (affecting up to 1 in 100 people). If symptoms of hypercalcaemia are observed, they are noted as a possible indication of elevated calcium levels.

Q: Are there any long-term health concerns associated with taking Ideos?

Concerns addressed in regulatory documents for long-term use relate to calcium levels. Official guidance emphasizes the requirement for regular monitoring of serum and urinary calcium levels and kidney function during prolonged use. Uncontrolled, continuous high calcium levels may potentially lead to damage to the kidneys and soft tissue calcification.

Q: Are there any special warnings about sun exposure while using Ideos?

Ideos contains Vitamin D3, which the body also produces in response to sunlight. Regulatory and health authority sources indicate that typical sun exposure does not lead to Vitamin D toxicity, but authoritative sources suggest the total intake of Vitamin D from all sources, including supplements and sunlight, is a factor in overall health assessment.

Q: What does the research say about Ideos for long-term use?

While regulatory documents do not provide a detailed summary of long-term efficacy studies, they mandate that patients on long-term treatment must undergo regular blood and urine tests. This monitoring is a requirement for ongoing safety assessment related to calcium levels and kidney function.

Q: Does Ideos affect fertility or reproductive health?

Official regulatory documents state that Ideos can be used during pregnancy and breast-feeding, but with a specific restriction. Due to the risk of Vitamin D overdose, the permitted daily use for these populations is limited to a specified amount.

Q: Is there a generic version of Ideos available?

Ideos is a fixed-combination product containing the active ingredients calcium carbonate and cholecalciferol (Vitamin D3). Official information indicates these components are commonly found in generic and non-prescription products.

Q: Is Ideos safe for people who are 65 and older?

The medicine is specifically indicated in official documents for use in the elderly population for deficiency correction. However, official guidance emphasizes that the monitoring of calcium levels and kidney function is advised for this group during prolonged treatment.

Q: Are there any specific lifestyle changes that can help Ideos work better?

Regulatory information advises that Ideos administration should be kept separate from meals containing high levels of oxalic acid (found in foods like spinach and rhubarb) or phytic acid (found in whole cereals and chocolate). Regulatory documents state that separation is advised because these substances are known to interfere with absorption of the medicine.

Q: Is the research on Ideos based on animal or human studies?

The primary body of evidence supporting the use and formulation of Ideos includes published data from multicenter, randomized controlled clinical trials conducted in human subjects. These types of studies are used to evaluate the drug's effects on the body's systems.

How should Ideos be stored and disposed of?

The official storage and disposal guidelines for Ideos (Calcium Carbonate/Cholecalciferol) are designed to maintain product integrity and environmental safety, as mandated by regulatory authorities.

Official Storage Requirements

Ideos chewable tablets must not be stored above 25°C. To protect the medicine from moisture and light, it is mandatory to store the tablets in the original container, which must be kept tightly closed. The product should not be used past the expiration date (EXP) shown on the packaging. A critical safety instruction is to always keep the medicine out of the sight and reach of children.

Disposal Instructions

Official labeling instructs that unused or expired Ideos must not be disposed of via household waste or flushed into wastewater. To comply with environmental protection requirements, the user must ask a pharmacist for guidance on the proper disposal of unwanted medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.